Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation Disorders | 5 | 2023 | 66 | 3.630 |
Why?
|
| Thrombelastography | 4 | 2023 | 47 | 2.600 |
Why?
|
| Plasma Exchange | 6 | 2021 | 30 | 2.300 |
Why?
|
| Prothrombin Time | 4 | 2024 | 22 | 2.160 |
Why?
|
| Blood Coagulation | 3 | 2023 | 92 | 1.560 |
Why?
|
| Anticoagulants | 8 | 2023 | 426 | 1.390 |
Why?
|
| Apolipoprotein A-I | 6 | 2014 | 70 | 1.340 |
Why?
|
| Antiphospholipid Syndrome | 3 | 2024 | 21 | 1.290 |
Why?
|
| Thrombocytopenia | 4 | 2023 | 187 | 1.170 |
Why?
|
| Erythrocyte Transfusion | 4 | 2024 | 72 | 1.170 |
Why?
|
| Blood Platelets | 5 | 2022 | 150 | 1.170 |
Why?
|
| Bone Marrow | 3 | 2024 | 445 | 1.090 |
Why?
|
| Blood Coagulation Tests | 4 | 2023 | 35 | 1.040 |
Why?
|
| Peptides | 6 | 2010 | 647 | 0.980 |
Why?
|
| Atherosclerosis | 6 | 2010 | 256 | 0.980 |
Why?
|
| Heparin | 5 | 2023 | 185 | 0.900 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 97 | 0.870 |
Why?
|
| Anemia, Sickle Cell | 2 | 2022 | 144 | 0.830 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 17 | 0.820 |
Why?
|
| Blood Transfusion | 2 | 2022 | 166 | 0.820 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2022 | 14 | 0.820 |
Why?
|
| Organ Preservation | 1 | 2022 | 105 | 0.810 |
Why?
|
| Hemophilia A | 2 | 2022 | 8 | 0.800 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 148 | 0.760 |
Why?
|
| Thrombosis | 5 | 2023 | 302 | 0.740 |
Why?
|
| Blood Banks | 1 | 2019 | 7 | 0.690 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2019 | 13 | 0.690 |
Why?
|
| Bone Marrow Examination | 1 | 2019 | 47 | 0.680 |
Why?
|
| Bone Marrow Diseases | 1 | 2019 | 40 | 0.680 |
Why?
|
| Lung Transplantation | 1 | 2022 | 290 | 0.630 |
Why?
|
| Humans | 45 | 2024 | 89073 | 0.620 |
Why?
|
| Factor XI Deficiency | 1 | 2017 | 1 | 0.610 |
Why?
|
| Hemorrhage | 2 | 2023 | 278 | 0.590 |
Why?
|
| Oxygen | 1 | 2022 | 742 | 0.570 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2023 | 168 | 0.550 |
Why?
|
| Isoantibodies | 3 | 2022 | 119 | 0.540 |
Why?
|
| Antibodies | 2 | 2022 | 353 | 0.500 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 1401 | 0.500 |
Why?
|
| Retrospective Studies | 8 | 2024 | 9003 | 0.480 |
Why?
|
| Receptors, LDL | 1 | 2014 | 54 | 0.470 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 228 | 0.470 |
Why?
|
| Drug Monitoring | 2 | 2017 | 119 | 0.460 |
Why?
|
| Factor Xa | 1 | 2013 | 4 | 0.460 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 338 | 0.460 |
Why?
|
| Pathology, Surgical | 1 | 2013 | 12 | 0.460 |
Why?
|
| Nanoparticles | 1 | 2014 | 164 | 0.430 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2022 | 13 | 0.410 |
Why?
|
| Platelet Aggregation | 2 | 2021 | 44 | 0.380 |
Why?
|
| Point-of-Care Testing | 3 | 2020 | 25 | 0.380 |
Why?
|
| Fibrinolysis | 2 | 2022 | 37 | 0.380 |
Why?
|
| International Normalized Ratio | 3 | 2020 | 39 | 0.380 |
Why?
|
| Extracorporeal Circulation | 2 | 2022 | 34 | 0.380 |
Why?
|
| Referral and Consultation | 1 | 2013 | 341 | 0.370 |
Why?
|
| Hemolysis | 2 | 2022 | 64 | 0.360 |
Why?
|
| Molecular Mimicry | 3 | 2010 | 20 | 0.350 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 130 | 0.350 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 2014 | 0.340 |
Why?
|
| Proline | 1 | 2009 | 55 | 0.330 |
Why?
|
| Hemoglobins | 3 | 2022 | 192 | 0.320 |
Why?
|
| Warfarin | 2 | 2019 | 104 | 0.320 |
Why?
|
| Acute-Phase Proteins | 1 | 2007 | 37 | 0.300 |
Why?
|
| Immunoglobulin G | 4 | 2023 | 464 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 345 | 0.290 |
Why?
|
| Necrosis | 2 | 2019 | 209 | 0.280 |
Why?
|
| Viper Venoms | 1 | 2024 | 5 | 0.250 |
Why?
|
| Biomarkers | 3 | 2021 | 1755 | 0.240 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2024 | 14 | 0.240 |
Why?
|
| Erythrocytes | 2 | 2022 | 254 | 0.240 |
Why?
|
| Janus Kinase 2 | 1 | 2024 | 60 | 0.240 |
Why?
|
| Vaccines | 2 | 2022 | 83 | 0.230 |
Why?
|
| Air Ambulances | 1 | 2024 | 25 | 0.230 |
Why?
|
| Fibrinolytic Agents | 2 | 2022 | 214 | 0.210 |
Why?
|
| von Willebrand Diseases | 1 | 2022 | 6 | 0.210 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 132 | 0.210 |
Why?
|
| Rivaroxaban | 1 | 2022 | 12 | 0.200 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 250 | 0.200 |
Why?
|
| Dabigatran | 1 | 2022 | 25 | 0.200 |
Why?
|
| Perfusion | 1 | 2022 | 235 | 0.190 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 2062 | 0.190 |
Why?
|
| Formaldehyde | 1 | 2021 | 52 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 56 | 0.190 |
Why?
|
| Thrombin | 1 | 2021 | 61 | 0.190 |
Why?
|
| Male | 10 | 2024 | 42254 | 0.190 |
Why?
|
| Shear Strength | 1 | 2020 | 18 | 0.190 |
Why?
|
| Device Approval | 1 | 2020 | 13 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 29 | 0.190 |
Why?
|
| Fibrinogen | 1 | 2020 | 53 | 0.180 |
Why?
|
| Indicators and Reagents | 1 | 2020 | 72 | 0.180 |
Why?
|
| Viscosity | 1 | 2020 | 46 | 0.180 |
Why?
|
| Elasticity | 1 | 2020 | 96 | 0.180 |
Why?
|
| Molecular Sequence Data | 3 | 2010 | 3027 | 0.180 |
Why?
|
| Reference Values | 1 | 2021 | 661 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2020 | 66 | 0.180 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2020 | 45 | 0.180 |
Why?
|
| Vibration | 1 | 2020 | 51 | 0.180 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.180 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 316 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2020 | 102 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 207 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 135 | 0.170 |
Why?
|
| Lipoproteins, LDL | 2 | 2010 | 85 | 0.170 |
Why?
|
| Transfusion Medicine | 1 | 2019 | 4 | 0.170 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2019 | 12 | 0.170 |
Why?
|
| HLA-A24 Antigen | 1 | 2019 | 19 | 0.170 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2019 | 20 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 129 | 0.170 |
Why?
|
| CD47 Antigen | 1 | 2019 | 23 | 0.170 |
Why?
|
| Vaccination | 1 | 2021 | 273 | 0.170 |
Why?
|
| Thrombolytic Therapy | 1 | 2022 | 232 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 154 | 0.170 |
Why?
|
| Equipment Design | 1 | 2020 | 415 | 0.170 |
Why?
|
| ABO Blood-Group System | 1 | 2019 | 58 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 189 | 0.170 |
Why?
|
| Ultrasonography | 1 | 2021 | 711 | 0.160 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2018 | 8 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 309 | 0.160 |
Why?
|
| Female | 10 | 2024 | 46014 | 0.160 |
Why?
|
| Platelet Factor 4 | 3 | 2022 | 12 | 0.160 |
Why?
|
| Myositis Ossificans | 1 | 2017 | 3 | 0.150 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 157 | 0.150 |
Why?
|
| Factor VIII | 1 | 2017 | 7 | 0.150 |
Why?
|
| Administration, Oral | 2 | 2022 | 682 | 0.150 |
Why?
|
| Animals | 9 | 2023 | 27324 | 0.140 |
Why?
|
| Mice | 5 | 2023 | 11742 | 0.140 |
Why?
|
| Adult | 7 | 2024 | 26508 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 788 | 0.140 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cesarean Section | 1 | 2017 | 140 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 967 | 0.140 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 46 | 0.130 |
Why?
|
| Lung | 1 | 2022 | 1258 | 0.130 |
Why?
|
| Mutation | 2 | 2024 | 4132 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2017 | 210 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 841 | 0.120 |
Why?
|
| Pregnancy | 2 | 2024 | 3010 | 0.120 |
Why?
|
| Aged | 5 | 2024 | 19078 | 0.120 |
Why?
|
| Middle Aged | 7 | 2024 | 25865 | 0.120 |
Why?
|
| Protein Structure, Secondary | 3 | 2010 | 332 | 0.120 |
Why?
|
| Laboratories, Hospital | 1 | 2013 | 8 | 0.120 |
Why?
|
| Biological Assay | 1 | 2013 | 79 | 0.110 |
Why?
|
| Factor Xa Inhibitors | 1 | 2013 | 23 | 0.110 |
Why?
|
| United States | 3 | 2020 | 6957 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 434 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3211 | 0.110 |
Why?
|
| Drug Overdose | 1 | 2013 | 71 | 0.110 |
Why?
|
| Neoplasms | 2 | 2019 | 3035 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 889 | 0.100 |
Why?
|
| Platelet Count | 2 | 2021 | 93 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 756 | 0.090 |
Why?
|
| Biopsy | 1 | 2015 | 1182 | 0.090 |
Why?
|
| Aryldialkylphosphatase | 1 | 2010 | 6 | 0.090 |
Why?
|
| Serum Amyloid A Protein | 1 | 2010 | 25 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2612 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 163 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2010 | 35 | 0.090 |
Why?
|
| Protein Transport | 2 | 2010 | 421 | 0.090 |
Why?
|
| Epitopes | 1 | 2010 | 255 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 369 | 0.090 |
Why?
|
| Spleen | 1 | 2010 | 432 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 120 | 0.080 |
Why?
|
| Biotinylation | 1 | 2009 | 42 | 0.080 |
Why?
|
| Biomimetic Materials | 1 | 2009 | 24 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 225 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 452 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2020 | 8203 | 0.080 |
Why?
|
| Young Adult | 2 | 2024 | 6289 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2009 | 352 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 269 | 0.080 |
Why?
|
| Adolescent | 2 | 2024 | 9237 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2015 | 3717 | 0.070 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 510 | 0.070 |
Why?
|
| Kinetics | 1 | 2009 | 1528 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1867 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2010 | 1990 | 0.060 |
Why?
|
| Disease Management | 2 | 2018 | 329 | 0.060 |
Why?
|
| Protein Binding | 1 | 2009 | 1487 | 0.060 |
Why?
|
| Erythroblastosis, Fetal | 1 | 2024 | 11 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2007 | 948 | 0.060 |
Why?
|
| Inflammation | 1 | 2010 | 971 | 0.060 |
Why?
|
| Child | 1 | 2015 | 7149 | 0.060 |
Why?
|
| Ristocetin | 1 | 2022 | 1 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2022 | 37 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 131 | 0.050 |
Why?
|
| Pathologists | 1 | 2022 | 27 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2022 | 74 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2022 | 18 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 16 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 374 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 55 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 76 | 0.050 |
Why?
|
| Cytapheresis | 1 | 2021 | 1 | 0.050 |
Why?
|
| Filtration | 1 | 2021 | 25 | 0.050 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 27 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 150 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.050 |
Why?
|
| Cell Separation | 1 | 2021 | 198 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2022 | 996 | 0.040 |
Why?
|
| Plasma | 1 | 2019 | 51 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 120 | 0.040 |
Why?
|
| Vitamin K | 1 | 2019 | 25 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 1012 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 604 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 6 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 16 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 19 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 181 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 76 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 120 | 0.040 |
Why?
|
| Ossification, Heterotopic | 1 | 2017 | 33 | 0.040 |
Why?
|
| Prognosis | 1 | 2024 | 3773 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 356 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 105 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 269 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 264 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 6777 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1043 | 0.020 |
Why?
|
| Clusterin | 1 | 2010 | 13 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2009 | 94 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 357 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1488 | 0.020 |
Why?
|